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ABSTRACT
In genomic deletions, gene haploinsufficiency might directly configure a specific 
disease phenotype. Nevertheless, in some cases no functional association can be 
identified between haploinsufficient genes and the deletion-associated phenotype. 
Transcripts can act as microRNA sponges. The reduction of transcripts from the 
hemizygous region may increase the availability of specific microRNAs, which 
in turn may exert in-trans regulation of target genes outside the deleted region, 
eventually contributing to the phenotype. Here we prospect a competing endogenous 
RNA (ceRNA) approach for the identification of candidate genes target of epigenetic 
regulation in deletion syndromes. 
As a model, we analyzed the 5q- myelodysplastic syndrome. Genes in 
haploinsufficiency within the common 5q deleted region in CD34+ blasts were 
identified in silico. Using the miRWalk 2.0 platform, we predicted microRNAs whose 
availability, and thus activity, could be enhanced by the deletion, and performed 
a genomewide analysis of the genes outside the 5q deleted region that could be 
targeted by the predicted miRNAs. The analysis pointed to two genes with altered 
expression in 5q- transcriptome, which have never been related with 5q- before.  
The prospected approach allows investigating the global transcriptional effect of 
genomic deletions, possibly prompting discovery of unsuspected contributors in the 
deletion-associated phenotype. Moreover, it may help in functionally characterizing 
previously reported unexpected interactions.
INTRODUCTION
The vast majority of human malignancies exhibits 
chromosomal rearrangements. These rearrangements span 
from deletions, duplication, balanced and unbalanced 
translocations, to the gain or loss of whole chromosomes, 
which are often associated [1-8].
Frequently, specific genomic rearrangements are 
associated with specific malignant phenotypes. 
One notable example is the Philadelphia 
chromosome being the hallmark of chronic myelogenous 
leukemia (CML). Philadelphia chromosome is the result 
of a balanced translocation involving chromosomes 9 
and 22 [9]. The final product of this rearrangement is 
the production of a chimerical protein (p210BCR-ABL) with 
constitutive tyrosine kinase activity, which is responsible 
for the CML clone expansion [10]. 
The study of the effects of translocations usually 
leads to the identification of genes at the breakpoints 
that gain or lose functions and that are causative of the 
phenotypes observed. 
Differently, the study of genomic deletions or 
duplications is less straightforward because of the rarity 
of homozygous deletions and since the involved regions 
are commonly gene-rich.
The main efforts to elucidate the effects of deletions 
have been focused on the study of every single gene coded 
within the deleted region. The rationale is that if a gene 
shows haploinsufficiency, a reduced amount and activities 




For example, in Williams syndrome the 7q11.23 
band is deleted. The deleted region includes more than 
25 genes, comprising the ELN gene. ELN gene codes for 
the elastin protein, and its haploinsufficiency is associated 
with the typical cardiovascular abnormalities of the 
syndrome [36].
Interestingly, very often this axiomatic relationship 
between genic deletion and phenotype is not easily 
identified. This is the case of 5q- syndrome [9], which we 
have adopted as a model to test a novel in silico approach 
to investigate the global effect of deletions. The 5q- 
syndrome is a hematological disorder characterized by 
the loss of the 5q31.1 band in bone marrow hematopoietic 
cells. This chromosome abnormality usually leads to a 
myelodysplastic syndrome (MDS) that can also evolve 
towards acute myeloid leukemia (AML) [37-42]. In the 
commonly deleted region of 5q-, several genes have 
been suggested to play a role in the syndrome, such as 
SPARC, RPS14 and hsa-miR-145, all of them contributing 
to specific features of the 5q- myelodysplasia. However, 
the reduced activity of such genes does not explain every 
facet of the complex phenotype of 5q- syndrome [37-42]. 
In order to investigate the global effect of the 5q 
deletion, we prospected a competing endogenous RNAs 
(ceRNA) approach. CeRNA rationale relies on the 
consideration that RNA transcripts regulate one another 
by competing for shared microRNAs [43-48]. The loss 
or haploinsufficiency of a specific gene can free a certain 
amount of regulating microRNAs that, in turn, can act 
in-trans to regulate a subset of other transcripts. CeRNA 
approach has given interesting results both in oncological 
and non-oncological diseases. Usually, competing RNAs 
are explored using a single bait gene, as in the case of 
PTEN [49, 50], LMNA [51, 52], SOX2 [53], hTERT [54]. 
To the best of our knowledge, the effect of the loss of a 
pool of genes, as in the case of a deletion, using a ceRNA 
approach, has never been investigated before.
In 5q- syndrome, we selected, by in silico 
analyses, a set of microRNAs that might be freed by the 
haploinsufficiency of the genes coded within the deleted 
region, and identified the genes that could be regulated by 
the microRNA set as a whole. 
This approach, which extends the research for 
ceRNAs from a single bait gene, to a set of genes, allows 
identifying those genes whose activity can be perturbed 
by a genomic deletion, considered as a whole. Notably, it 
could provide an explanation to the phenotypes observed 
in syndromes caused by deletions, independently from the 
genes coded within the deleted region. 
RESULTS AND DISCUSSION
Over the last few years, it has become clear that 
different RNA species can cross-talk and regulate one 
another [43-48, 55-59]. Due to a hemizygosis condition, 
several species of RNAs can be downregulated compared 
to a wild type condition. This global loss of transcripts 
might have an impact on the RNA-mediated cellular 
systems of regulation. In particular, we investigated if this 
loss of transcripts could have an impact on microRNA-
mediated systems of regulation. MicroRNAs are small 
non-coding RNAs that regulate the gene expression, 
mostly at a post-transcriptional level [60-64]. In particular, 
RNA transcripts can regulate one another by competing for 
shared microRNAs. The RNAs that regulate one another 
in this way are called competing endogenous RNAs or 
ceRNAs. Competitive endogenous RNAs cross-regulation 
involves sequestration of shared microRNAs and gives 
rise to rather complex regulatory networks [43-48]. 
The loss of several transcripts at once during a 
deletion might free a sufficient amount of microRNAs 
that can assert a detectable effect in trans outside 
from the deleted region. Moreover, if several genes in 
haploinsufficiency within the deleted region are regulated 
by the same set of microRNAs, we might be able to 
identify a deletion-specific signature characterized by an 
increased activity of specific microRNAs.
In brief, a deletion could have an impact on the 
activity of a specific set of microRNAs that may in turn 
alter the activity of genes outside the deleted region and 
apparently unrelated with the genomic deletion. This 
alteration might contribute to determine the phenotypes of 
deletion syndromes.
In order to test our hypothesis, we used the 5q- 
syndrome model to investigate if a ceRNA approach 
could be useful to identify unexpected contributors to 
deletion syndromes. The approach adopted is graphically 
summarized in Figure 1. 
We took advantage of the published GDS3795 
affymetrix array dataset [65], which collects the global 
gene expression profiling of bone marrow CD34+ cells of 
myelodysplastic syndrome patients and healthy controls. 
We first identified the patients with 5q deletion as 
the only reported genomic abnormality (see Supplemental 
data), and then, using their expression data, we selected 
the genes in haploinsufficiency within the common 5q 
deleted region, which are listed in Table 1. 
Using the bioinformatics approach described in the 
Methods section, we identified a set of microRNAs that 
putatively regulate the genes in haploinsufficiency. Each 
gene was regulated by a different set of microRNAs, but 
overall some microRNAs regulate a larger set of genes. 
Organizing those microRNAs in a hierarchical order, we 
were able to identify the most represented microRNAs. 
MicroRNAs that putatively regulated at least 5 of the 
haploinsufficient genes within the 5q- deleted region were 
selected. These included: hsa-miR-3164, hsa-miR-513a-
5p, hsa-miR-30c-1-3p, hsa-miR-1254, hsa-miR-3916, 
hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-4311, and 
hsa-miR-665 (see Supplemental data).
We then looked for genes that were predicted to be 
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Table 1: Identification of haploinsufficient genes within the commonly deleted region of 5q-.
Gene name Mean 5q- SD 5q- SE 5q- Mean CNTR SD CNTR SE CNTR p-value p <0.05
ABLIM3 48.59779 58.31375 10.82859 22.49942 4.97781 1.2073 0.07359  
AFAP1L1 12.05416 3.3277 0.61794 15.09705 3.75227 0.91006 0.00653 DOWN
ANXA6 122.24087 67.11685 12.46329 147.35532 52.42362 12.7146 0.19289  
ARHGEF17 147.6068 37.55099 6.97304 133.18229 28.94435 7.02004 0.18011  
ARSI 19.25328 3.34174 0.62055 20.23331 7.4089 1.79692 0.54062  
ATOX1 193.08972 81.26299 15.09016 211.23735 30.26857 7.34121 0.38248  
CAMK2A 32.69334 10.36123 1.92403 32.51296 10.37561 2.51645 0.95483  
CCDC69 63.50043 31.51593 5.85236 107.38927 32.08788 7.78245 0.00004 DOWN
CD74 38.76174 8.96062 1.66395 40.6401 7.54131 1.82904 0.47179  
CSF1R 79.69017 44.38093 8.24133 106.02755 38.34201 9.2993 0.04748 DOWN
CSNK1A1 59.94675 54.80374 10.1768 101.51224 49.24745 11.94426 0.01347 DOWN
DCTN4 47.74753 16.37672 3.04108 68.13771 18.98236 4.6039 0.00039 DOWN
FAT2 19.86582 3.65128 0.67803 20.04196 3.26452 0.79176 0.87047  
G3BP1 57.54757 22.68119 4.21179 83.12785 23.39945 5.6752 0.00069 DOWN
GLRA1 12.83507 1.82292 0.33851 12.48884 1.03018 0.24986 0.4773  
GM2A 36.88007 10.41824 1.96886 46.9379 9.92848 2.40801 0.00262 DOWN
GPX3 36.37417 33.64503 6.24773 37.93556 27.76831 6.73481 0.87237  
GRPEL2 64.30569 23.59284 4.38108 98.69718 30.05175 7.28862 0.00009 DOWN
HMGXB3 92.76827 22.19641 4.12177 129.66734 24.83669 6.02378 0.000005 DOWN
IL17B 23.57699 3.80584 0.70673 25.38715 2.49688 0.60558 0.08732  
IRGM 8.72469 1.41946 0.26359 9.03116 0.93882 0.2277 0.43232  
LOC100652758  Data not available
MIR143HG 45.98064 7.97738 1.48136 44.04348 5.67301 1.37591 0.38484  
MYOZ3 126.92361 34.89592 6.48001 138.42359 30.43793 7.38228 0.26498  
NDST1 60.03087 27.17387 5.04606 58.14676 23.76045 5.76275 0.81347  
PCYOX1L 117.69138 49.35714 9.16539 166.65525 69.23529 16.79202 0.0077 DOWN
PDE6A 23.06221 12.30975 2.28586 20.27092 2.3138 0.56118 0.36191  
PDGFRB 23.11002 7.09533 1.31757 23.33169 3.82961 0.92882 0.90605  
PPARGC1B 44.98414 17.74701 3.29554 85.30953 26.02103 6.31103 0.0000001 DOWN
RBM22 63.53639 26.10673 4.8479 94.33986 17.52159 4.24961 0.00009 DOWN
RPS14 7856.9131 1234.65184 229.26909 10598.78235 941.02851 228.23294 0.0000000006 DOWN
SH3TC2 14.87956 4.13834 0.76847 14.6208 3.05314 0.7405 0.82371  
SLC26A2 114135 53.33529 9.90411 200.29804 70.23587 17.0347 0.00003 DOWN
SLC36A1 44.44143 14114 2.6209 46.69696 15.60091 3.78378 0.61728  
SLC36A3  Data not available
SLC6A7 46.04152 6.0099 1.11601 47.21034 6.08871 1.47673 0.52959  
SMIM3 260.38469 141.71754 26.31629 500.79865 310.45128 75.2955 0.00081 DOWN
SPARC 49.30088 41.99314 7.79793 62.24083 28.91624 7.01322 0.26807  
SYNPO 110.19731 20.31167 3.77178 115.67666 15.80301 3.83279 0.34516  
TCOF1 57.14866 25.18242 4.67626 73.23271 19.88939 4.82388 0.02946 DOWN
TIGD6 7.45674 0.79702 148 7.39382 0.78457 0.19029 0.79614  
TNIP1 139.14645 86.98013 16.1518 154.56547 45.26099 10.9774 0.50195  
ZNF300 96.84063 73.90228 13.72331 86.83198 35.88454 8.70328 0.60446  
A comparison of the normalized expression levels, as reported in GDS3795 dataset, of the genes within the common 
deleted region between 5q- patients and controls. The genes that showed in a student’s t-test a statistically significant 
(p<0.05) reduction of expression levels in 5q- specimens were considered as haploinsufficient genes. SE= Standard Error. 
SD= Standard Deviation. CNTR= Controls.
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regulated by all of the 9 microRNAs, the rationale being 
that if these microRNAs could not bind a fraction of 
their natural targets due to the haploinsufficiency of the 
5q-coded genes, they were free to exert their control on 
the remaining targets, deregulating the control network.
The analysis pointed out 4 genes, namely DCX, 
GRAMD1B, HIPK2 and SLC1A2, which were putatively 
regulated by all the 9 microRNAs. Among these genes, 
GRAMD1B and HIPK2, showed significantly different 
mRNA expression in 5q- CD34+ cells as compared with 
control CD34+ cells in the same GDS3795 dataset, being 
significantly down- and up-regulated, respectively. Of 
note, the two genes that did not show significant variation 
between 5q- and control CD34+ cells both showed very 
low expression levels (Table 2). 
GRAMD1B codes for a protein involved in 
chemoresistance [66] and the rs735665 SNP upstream 
of its coding sequence has been associated with chronic 
lymphocytic leukemia (CLL) in a genome-wide 
association study [67, 68].
HIPK2 is part of the AML1 complex, and it 
activates its transcriptional activity. Noteworthy, AML1 is 
a frequent target of leukemia-associated mutations. It has 
been reported that HIPK2 mutations in AML and MDS 
impair AML1-mediated transcription. It has been therefore 
suggested that a deregulation of HIPK2 may play a role in 
the pathogenesis of leukemia [69].
The results obtained through the approach 
prospected herein have, however, some limitations. 
Indeed, the algorithms used to identify the interactions 
Table 2: Expression levels of the putative ceRNA genes in 5q- samples compared with the controls.




CNTR p-value p <0.05
DCX 11.62274 1.82978 0.33978 10.91179 1.54032 0.37358 0.18543  
GRAMD1B 173.15608 48.10625 8.93311 217.83253 40.57191 9.84013 0.00245 DOWN
HIPK2 270.99334 102.12731 18.96457 213.90735 66.42774 16.11109 0.04549 UP 
SLC1A2 15.62593 2.33554 0.4337 16.00038 2.37252 0.57542 0.60439  
A comparison of the normalized expression levels, as reported in GDS3795 dataset, of the putative ceRNA genes between 5q- patients and controls. The 
genes that showed in a student’s t-test a statistically significant (p<0.05) difference of expression levels are considered as positive results. SE= Standard 
Error. SD= Standard Deviation. CNTR= Controls. 
Figure 1: Schematic representation of the ceRNA analysis on 5q deletion. a. The ideogram of human 5 chromosome (modified 
from David Adler); b. The genes within the common deleted 5q- region (the genes in haploinsufficiency are in bold); c. The microRNAs 
that regulated 5 or more genes in haploinsufficiency in b; d. The genes that are regulated by the 9 microRNAs in c and that are considered 
the putative ceRNAs (in bold the genes that show a significant different expression in 5q- patients compared with the controls).
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between transcripts and microRNAs are still imperfect. 
Even if the criterion used was highly stringent (i.e. the 
contemporary detection by 4 of the most used algorithms) 
the certainty of the result is far from being achieved. 
The adoption of different algorithms and/or different 
parameters could lead to different results. 
Similarly, the adoption of a different, and less 
stringent threshold in the selection of microRNAs could 
have led to different results. 
Finally, the interpretation of the results is rather 
complex. If microRNAs can act only as inhibitors of 
transcription and translation, the ceRNAs isolated through 
this analysis should have been consistently downregulated. 
Instead, the analysis identified HIPK2 that is significantly 
upregulated in the 5q- patients as compared with 
controls. It is known that microRNAs can also upregulate 
the transcription [70-72], and maybe that is the case. 
Alternatively, HIPK2 upregulation could be the result of 
complex perturbations of the RNA regulatory network. 
Nevertheless, the analysis that we prospected 
was able to pinpoint two genes significantly modulated 
in patients, as compared with controls, and whose 
relationship with 5q- deletion was never reported before.
The method prospected here represents a novel 
approach to study the global effects of genomic deletions 
with the final aim of identifying unexpected contributors 
to the genomic deletion phenotypes and could deserve 
experimental validation. The same approach might be used 
to study duplications or complex rearrangements, leading 
to a new strategy to question complex syndromes and 
phenotypes that at the moment are not fully understood. 
MATERIALS AND METHODS
The published GDS3795 affymetrix array dataset 
[65] was used to select the genes in haploinsufficiency 
within the common 5q deleted region [73] in bone marrow 
CD34+ cells of myelodysplastic syndrome patients. We 
selected patients that showed only 5q- deletion without 
other reported rearrangements. In detail, we selected 29 
patients (MDS patient 4, 5, 6, 7, 8, 10, 11, 12, 14, 15, 
21, 23, 24, 26, 31, 35, 36, 45, 58, 62, 70, 90, 95, 109, 
121, 132, 135, 154, 168) and compared them with the 17 
healthy controls of the dataset (Supplemental data).
The expression levels of the genes within the 
common deleted region between 5q- patients and controls 
were compared. The genes that showed in a student’s 
t-test a statistically significant (p < 0.05) reduction of 
expression levels in 5q- specimens were considered as 
haploinsufficient genes (Table 1). As expected, no genes 
showed an increase in expression levels.
The miRWalk 2.0 [74] platform was used to 
identify the microRNAs that putatively regulate the 
genes in haploinsufficency. We considered as positives 
the microRNAs that recognize the 3’UTR of the genes, 
with a minimum seed length of 7 and from miRNA seed 
position 1, with a maximum of p-value of 0.05 in all of the 
4 algorithms embedded in the platform used during the 
analysis: miRWalk [74], miRanda [75], RNA22 [76] and 
TargetScan [77]. If a gene was recognized multiple times 
by the same microRNA, it was considered as a single hit 
in the following analyses. This collection of microRNAs 
was then organized in a hierarchical order from the most 
present to the less, and only microRNAs that putatively 
regulated 5 or more genes in haploinsufficiency were 
selected for the following analyses. The threshold of 5 
was selected to harvest a sufficient number of microRNA 
to continue the analysis, ideally in the range of the number 
of microRNAs that can control a single gene, from 4 to 20 
[78] (Supplemental data). 
Using the miRWalk 2.0 platform with the same 
parameters described above, the genes putatively regulated 
by this pool of microRNAs were identified, and those 
genes that resulted regulated by all the microRNAs 
were selected. The expression levels of the candidate 
genes were then analyzed in the same samples from the 
GDS3795 dataset. 
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